RHÖN-KLINIKUM AG | 08/04/2016

Interim Report for the First Six Months of 2016: RHÖN-KLINIKUM AG Continues its Strong Growth – Strategic Focus on Network Medicine and Digitalisation

  • 414,403 patients treated
  • Revenues stand at Euro 590.6 million
  • EBITDA in the amount of Euro 103.4 million includes dissolving provisions of Euro 41 million
  • Outlook for 2016 remains unchanged: Revenues between Euro 1.17 billion and Euro 1.20 billion, EBITDA between Euro 155 million and Euro 165 million

Bad Neustadt / Saale, 4 August 2016

RHÖN-KLINIKUM AG continued its strong growth during the first six months of the current financial year 2016. In the first half-year a total of 414,403 patients were treated in the corporate hospitals at the five different sites. Revenues for the period from January up to and including June stood at Euro 590.6 million. Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to Euro 103.4 million including provisions of roughly Euro 41 million which had mainly been set aside for warranty claims from the sales transaction with Fresenius/Helios and were dissolved in the first six months of the financial year. The current financial figures are therefore not directly comparable with those of previous years due to these ongoing effects on the balance sheet.



For financial year 2016 we expect revenues of Euro 1.17 billion to Euro 1.20 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between Euro 155 million and Euro 165 million. Positive and negative one-off effects, the size of which will be a low to medium two‑digit million figure, will continue to influence the corporate results during this financial year as well and will partially cancel each other out. They mainly result from handling the transaction with Fresenius/Helios, the initial consolidation and integration of the municipal hospital in Bad Neustadt, special budgets for innovation and e-health, unresolved accounting issues and setting up a substantial diagnostic and out-patient clinic at the university hospital in Marburg.

Further legislative restrictions which will temporarily have a negative impact on the organic growth of the Company are currently to be expected in the largely regulated market environment in Germany. The Company must expect a drop in revenues of roughly 1 % for the current financial year arising, in particular, from the discounts on additional volume which were agreed in 2013; corresponding counteractive measures have already been introduced to neutralise the effects.

“It remains to be seen how the new law to reform the structures of hospital care (Krankenhausstrukturgesetz – KHSG) will affect our business in the medium to long term. Individual aspects of state-of-the-art healthcare will in particular probably be subjected to a new basis for calculation weighted in accordance with the heavier burdens,“ CEO Dr. Martin Siebert stated. “We are prepared for this new challenge. We shall also be strong enough in the future to persevere successfully and profitably in a continuously demanding market environment.”

“With targeted investments the Company will further develop and strengthen its primary position to provide maximum cutting-edge medical care with a direct link to universities, focussing particularly on digitalisation and network medicine, the principal issues of the future. Together with the Company’s campus concept all these initiatives form the basis of guaranteeing forward-looking healthcare which is constantly geared to patient needs,” Siebert added.